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Introduction
Inflammatory bowel diseases (IBDs), including Crohn’s disease 
and ulcerative colitis, are T cell–mediated, chronic disorders 
whose development is influenced in part by dysregulated, aggres-
sive intestinal mucosal immune reactions to resident intestinal 
bacteria (1–3). Enteric microbiota is essential for inducing and 
exacerbating chronic, immune-mediated intestinal inflammation 
in most rodent models of IBD. This has been most clearly demon-
strated in gnotobiotic experiments in which most germ-free (GF), 
genetically susceptible mice and rats exhibit minimal intestinal 
inflammation and immune activation, but rapidly develop chron-
ic colitis and pathogenic T cell–mediated immune responses after 
colonization with specific pathogen–free (SPF) or specific enter-
ic bacteria (4–6). Recent studies have identified microbial fac-
tors that selectively stimulate pro- or antiinflammatory immune 
responses in the intestine. For example, segmented filamentous 
bacteria strongly activate largely proinflammatory Th17 responses 
in the small intestine (7). On the other hand, in normal hosts, some 
resident enteric bacterial species stimulate regulatory immune 
responses that help maintain intestinal mucosal homeostasis. 
Selected Clostridium species induce mucosal Foxp3+CD4+ T cells 
(8), and Bacteroides fragilis polysaccharide A stimulates IL-10–pro-
ducing Tregs (9). However, these bacteria coexist in a consortium 
with many other species in the complex mammalian intestinal 
ecosystem, where a delicate balance of putative pro- and antiin-
flammatory species helps maintain mucosal homeostasis. In IBD, 
a characteristic expansion of putative aggressive bacterial groups 
and contraction of protective species (dysbiosis) is thought to con-
tribute to IBD pathogenesis (1–3). Additional mechanistic studies 
are required in order to better understand how these resident bac-
terial communities interact with the host immune system to main-
tain intestinal homeostasis or cause IBD.
IL-10 inhibits proinflammatory, effector innate, and adaptive 
immune cells and helps maintain mucosal homeostasis. Mice with 
genetic deletion of IL-10 or the IL-10 receptor (IL-10R) sponta-
neously develop Th1/Th17-mediated colitis when normal enteric 
microbiota is present (4, 5, 10), while administration of exogenous 
recombinant IL-10 prevents the onset of experimental enteroco-
litis, improves epithelial barrier function, and inhibits microbio-
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production is based mainly on in vitro studies using cell lines, bone 
marrow–derived cells, and narrowly defined stimulants, with con-
flicting results in different cell types (31). Therefore, further in 
vivo mechanistic studies in mucosal immune cells stimulated with 
physiologically relevant microbial stimuli are needed to more fully 
understand how IL-10 mediates intestinal homeostasis.
Given our recent work demonstrating a protective role of 
bacteria-stimulated IL-10–secreting B cells through activation of 
Tregs in chronic colitis and the ability of bacterial lysates to stimu-
late the regulatory capacity of B cells in vitro (23), we hypothesized 
that TLR-dependent IL-10 production by resident bacteria is crit-
ical for B cell–mediated protection against experimental colitis. In 
this study, we demonstrate that resident enteric bacteria promote 
the in vivo development of IL-10–producing colonic lamina pro-
pria (LP) immune cells, especially T cell subsets and B cells. Intes-
tinal bacterial colonization transiently activated proinflammatory 
ta-stimulated, proinflammatory cytokine production in the muco-
sa (4, 11–13). In addition, IL-10 or IL-10R gene polymorphisms 
are associated with ulcerative colitis and early onset of Crohn’s 
disease (14–16). IL-10 is produced by many types of immune cells, 
including CD4+ and CD8+ T cells, B cells, macrophages, DCs, 
neutrophils, NK cells, innate lymphoid cells, and eosinophils (17). 
Multiple studies implicate IL-10–producing regulatory CD4+ T cell 
subsets (Tregs, T regulatory 1 [Tr1] cells) in mucosal homeostasis 
(8, 18–20), while we and others have reported that IL-10–produc-
ing antigen-presenting cells (APCs) (21, 22) and regulatory B cells 
(23–28) are present in humans and prevent bacterial antigen-driv-
en, T cell–mediated chronic experimental colitis.
Previous in vitro studies have demonstrated that TLR and 
Myd88 signaling contributes to the development of bacteria-in-
duced, IL-10–secreting immune cells (24, 29, 30). However, our 
current understanding of how bacterial products stimulate IL-10 
Figure 1. Resident intestinal microbiota increases the frequency of intestinal IL-10–producing immune cells and enhance IL-10 production. (A) Left: 
Spontaneous IL-10 secretion by colonic tissue explants; middle: number of total IL-10–producing (GFP+) colon LP cells; right: Il10 mRNA expression in distal 
colon tissue normalized by expression in GF mice in GF, SPF-raised, or GF-conventionalized Il10+/EGFP reporter mice 3 days and 7 days (D3 and D7) after 
fecal transplantation (TP) with SPF feces. n = 6–9 mice/group, combined from 2 independent experiments. (B and C) Phosphorylation levels of STAT3 in 
the distal colon were evaluated by Western blot analysis and quantified by densitometry. n = 4 mice/group. (D) IL-10–producing (GFP+) colon LP cells were 
characterized by flow cytometry identifying cell subsets with antibodies to the indicated cell surface proteins. CD25–CD4+ T cells (CD25–CD4+CD3+), B cells 
(B220+CD19+), and Tregs, including GFP+Foxp3+RORγt+CD4+ T cells within the total GFP+Foxp3+CD4+ T cell population. n = 5–7 mice/group, combined from 
2 independent experiments. (E) Representative dot plots for colon LP GFP+CD25–CD4+ T cells (CD4+ T cell–gated) and GFP+ B cells (B cell–gated) in GF and 
conventionalized day 7 Il10+/EGFP mice. For flow cytometry, the GFP+ population in live CD45+ colon LP cells was assessed using WT (GFP–) cells stained with 
the same antibodies as target samples as a control (see Flow cytometry in Methods). All data are presented as median values; *P < 0.05, **P < 0.01, ***P 
< 0.001, Kruskal-Wallis test with Dunn’s post hoc test.
required for intracellular staining of IL-10. We first verified that 
GFP+ cells in our Il10+/EGFP reporter mice were suitable for inves-
tigating the kinetics of IL-10–producing cells by PCR, ELISA, 
and flow cytometry. We found that GFP+ B cells were function-
al, producing abundant IL-10 and lower levels of inflammatory 
cytokines compared with GFP– B cells following TLR ligation 
(Supplemental Figure 1, A–C; supplemental material available 
online with this article; https://doi.org/10.1172/JCI93820DS1). 
We developed flow cytometry methods and gating strategies to 
measure low-frequency GFP+ cells based on basal levels of GFP 
fluorescence intensity in WT SPF mice and stained WT cells with 
the antibodies used for target samples (Supplemental Figure 1D). 
Our results demonstrating that the number of GFP+ cells close-
ly correlated with tissue IL-10 protein and gene expression (see 
below) validated the use of GFP+ cells to measure physiologic 
IL-10 activation in vivo.
Next, to investigate whether resident bacteria induce colonic 
IL-10 and the kinetics of this response, we colonized GF IL-10–
sufficient Il10+/EGFP reporter mice and GF Il10−/− mice with feces 
cytokines in the colon in conjunction with prolonged stimulation 
of IL-10 in ex-GF Il10+/+ mice, but led to sustained aggressive acti-
vation of inflammatory cytokines in the absence of IL-10. We also 
show that TLR2 and MyD88 signaling is essential for bacteria- 
inducible IL-10–producing B cells to regulate T cell–mediated 
colitis and that TLR2-dependent bacterial activation of IL-10 pro-
duction by B cells is mediated through the PI3K pathway. These 
findings increase our understanding of the pathogenesis of IBD 
and regulation of mucosal homeostasis by resident microbiota.
Results
Resident enteric microbiota increases intestinal IL-10–producing T 
and B cells in vivo. We used a combination of in vivo and in vitro 
strategies to elucidate how resident intestinal bacteria and their 
components stimulate protective IL-10 production by colonic LP 
immune cells. We employed the Il10+/EGFP reporter mice (32) that 
we derived GF (23). This model allowed us to explore the kinet-
ics and types of IL-10–producing colonic LP cells activated by 
resident bacterial colonization without the ex vivo manipulation 
Figure 2. Distribution and characteris-
tics of SPF mucosal and splenic GFP+ 
T and B cells. Physiological IL-10–pro-
ducing immune cells were characterized 
in colonic LP, MLN, and spleen from 
SPF-raised Il10+/EGFP reporter mice. (A) 
Percentages of cell types among total 
GFP+ cells were assessed by flow cytom-
etry using antibodies to cell surface 
markers as described in Methods, Flow 
cytometry. (B) Immunofluorescence was 
performed on distal colon tissue from 
SPF-reared Il10+/EGFP mice to characterize 
the distribution of GFP+ B cells and GFP+ 
T cells in lymphoid aggregates and the 
LP of the distal colon. GFP+ cells are 
shown in green. B cells (B220+) and T 
cells (CD3+) are shown in red. Merged 
images show B and T cells that are 
GFP+. Scale bars: far left column, 50 
mm; right panels, 20 mm.
types significantly increased compared with GF levels (Figure 1D, 
right, gray bars). These results indicate that subsets of B cells and 
CD4+ T cells are important sources of microbiota-activated IL-10 
production in the colonic LP. Further, the proportions of GFP+ 
cell populations in mesenteric lymph nodes (MLNs) and spleen 
were not significantly altered by bacteria colonization (Supple-
mental Figure 3D), indicating that the observed changes were 
selectively induced in the colon during the experiment. These 
results demonstrate that bacterial colonization of GF adult mice 
stimulates progressively increased IL-10 production, which after 
7 days approaches levels seen in SPF mice colonized at birth with 
resident microbiota. This IL-10 induction is slow, with significant 
increases in IL-10 levels compared with baseline GF levels occur-
ring only after 7 days.
Distribution and lineage of IL-10–producing immune cells in SPF 
mice. We next evaluated the distribution and lineage of physiologic 
IL-10–producing immune cells. In mice raised in SPF conditions 
from birth, CD4+ T cells were the most abundant type of IL-10+ cells 
in the colon LP (61.9%), followed by B cells (27.8%). B cell frequen-
cy among IL-10+ cells of the colon LP was similar to that observed in 
the spleen and MLNs (Figure 2A). Colonic GFP+B220+CD19+ cells 
expressed CD5+CD1dhiCD21hiCD23–CD24hiMHC-IIhiIgMloIgDlo, 
sharing certain phenotypic features with splenic marginal zone B 
cells and B10 cells (35) (Supplemental Figure 4). Compared with 
GFP– B cells, GFP+ LP B cells had lower IgM and IgD levels and 
higher CD24 intensity. In mice raised in SPF conditions, IL-10–
producing B cells were located primarily within colonic muco-
sal lymphoid aggregates, while GFP+ T cells were more diffusely 
distributed in both the LP and lymphoid aggregates (Figure 2B). 
Similarly, chronic mucosal inflammation induced by repeated 
dextran sulfate sodium administration for 3 cycles in the presence 
of resident bacteria markedly increased total mucosal IL-10+ cells 
(Supplemental Figure 5A), with diffuse expansion of GFP+ T cells 
in the LP; in contrast, GFP+ B cells remained limited to the lym-
phoid aggregates (Supplemental Figure 5, B–D), as seen in non-
inflamed mice (Figure 2B). Together, these results indicate that 
accumulation of certain subsets of IL-10–producing T and B cells 
in the colonic LP depends on the presence of microbiota, and 
these cells’ prevalence increases with inflammation. This finding 
is consistent with previously reported induction of regulatory B 
cells by IL-1β and IL-6 (30).
IL-10 regulates proinflammatory genes induced by bacterial colo-
nization. Because IL-10 regulates mucosal homeostasis, we inves-
tigated the kinetics of other inflammatory and regulatory intes-
tinal immune responses in ex-GF mice colonized with resident 
enteric bacteria with and without endogenous IL-10. To do this, we 
examined real-time PCR expression of immune-related transcrip-
from a WT isogenic C57BL/6J mouse housed in SPF conditions 
and measured various immune functions 3 and 7 days later. Age- 
and sex-matched adult mice raised in GF or SPF conditions served 
as controls. We confirmed by 16S rRNA assays that SPF bacteria 
stably colonized the intestines of ex-GF mice (Supplemental Fig-
ure 2). Spontaneous IL-10 secretion by ex vivo cultured colonic 
tissue explants, the frequency of GFP+ IL-10 reporter cells in the 
colonic LP, and Il10 mRNA expression in the distal colon signifi-
cantly increased over time after SPF enteric bacterial colonization 
(Figure 1A). The frequency of GFP+ LP cells strongly correlated 
with tissue Il10 mRNA expression (Supplemental Figure 1E) and 
protein secretion (Supplemental Figure 1F). In addition, SPF bac-
terial colonization was associated with significantly greater colon-
ic levels of phosphorylated STAT3, a key downstream molecule in 
both IL-10 and IL-6 signaling (Figure 1, B and C). These results 
suggest that the induction of IL-10 is associated with functional 
signaling, though we did not investigate the relative contributions 
of IL-10 versus IL-6 in activating STAT3.
We then sought to determine which subsets of colonic LP 
immune cells produce IL-10 in response to bacterial colonization. 
Bacterial colonization was associated with greater proportions of 
GFP+ B cells and Tr1 cells (Foxp3negCD25–CD4+ T cells) (Figure 1, 
D and E, and Supplemental Figure 3A), while proportions of GFP+ 
macrophages, DCs, CD8+ T cells, and CD25+CD4+ T cells were 
not significantly altered (Supplemental Figure 3B). Although the 
frequency of total Foxp3+ Tregs was not significantly altered by 
SPF fecal colonization (Supplemental Figure 3C), a newly iden-
tified Treg population (Foxp3+RORγt+IL-10+CD4+ T cells) (33, 
34) capable of greater immune suppression than the other Treg
Figure 3. Bacterial colonization influences the gene expression kinetics 
of the majority of proinflammatory cytokines in an IL-10–dependent 
fashion. Kinetic expression of selected genes in distal colons from GF, SPF-
raised (SPF), and ex-GF conventionalized (3 and 7 days after fecal trans-
plantation) Il10+/EGFP reporter mice (Il10+/+) or Il10–/–mice was determined by 
real-time PCR of colonic tissues. All gene expression was normalized with 
Actb. n = 6 mice/group, combined from 2 independent experiments. Data 
are presented as median; *P < 0.05, **P < 0.01, ***P < 0.001, Kruskal-Wal-
lis test with Dunn’s post hoc test.
with the lack of significant changes in the frequency of total LP 
Foxp3+ T cells in GF, ex-GF-colonized, and SPF mice (Figure 1D 
and Supplemental Figure 3, C and E). To determine the role of 
endogenous IL-10 in regulating these proinflammatory genes, we 
preformed similar studies in Il10–/– mice. In contrast to the tran-
sient increase in inflammatory genes in WT mice, colonization 
of Il10–/– mice with identical SPF fecal microbiota was associated 
with a far more robust and persistent increase in proinflammatory 
cytokine gene expression in the distal colon, with levels 1- to 2-log 
higher than in Il10+/+ mice (Figure 3). We had previously shown 
similar bacterial composition up to 1 week after fecal transplanta-
tion in WT and Il10–/– mice (36). Tgfb1 was also continuously upreg-
ulated in Il10–/– mice (data not shown), suggesting that transient 
upregulation of proinflammatory cytokine genes with subsequent 
suppression in Il10+/+ animals was either mainly IL-10 dependent 
or that an antiinflammatory effect of TGF-β1 was negated in the 
absence of IL-10. These results suggest that resident bacteria–
induced IL-10 helps maintain intestinal homeostasis by down-
regulating aggressive proinflammatory responses induced by res-
ident microbiota. This conclusion is consistent with our previous 
observation that in vivo neutralization of IL-10R increases IFN-γ 
responses to resident bacterial antigens (13).
tion factors and cytokines in whole tissue from the distal colons 
of Il10+/EGFP (Il10+/+) and Il10–/– mice reared GF, SPF-colonized 
ex-GF, or SPF, following the same time course used to study IL-10 
induction (Figure 1A). Regulatory Il10 and Tgfb1 were persistently 
upregulated in Il10+/+ mice after colonization with bacteria (Figure 
1A and Supplemental Figure 3E). In contrast, expression of innate 
proinflammatory cytokine genes, including Tnfa and Il6, was tran-
siently upregulated 3 days after colonization (Figure 3), but down-
regulated by 7 days, when colonic IL-10 reached higher levels (Fig-
ure 1A). The primarily adaptive cytokine genes Ifng and Il12b and 
transcription factor Tbet were continuously expressed up to 7 days 
after colonization, but expression of these genes was not different 
between GF and SPF mice (Figure 3 and Supplemental Figure 3E), 
suggesting that either more prolonged stimulation after bacterial 
exposure or early-life exposure to microbiota is required in order 
to downregulate these cytokines. In contrast, Il17a expression did 
not increase following bacterial colonization of GF mice, but was 
higher in mice born SPF than in GF mice. Rorgt was persistently 
upregulated in Il10+/+ mice (Supplemental Figure 3E), which might 
be associated with induction of Foxp3+RORγt+IL-10+ Tregs (Figure 
1D, right). Moreover, whole colonic tissue Foxp3 mRNA expression 
was not significantly altered by bacterial colonization, consistent 
Figure 4. CBL stimulates IL-10–producing colonic LP B cells ex vivo. Unfractionated colonic LP cells from GF or SPF-reared Il10+/EGFP reporter mice were cul-
tured with 0–100 μg/mL CBL from SPF mice for 2 days, as indicated. (A) The frequency of GFP+ cells was assessed by flow cytometry. conc., concentration. 
(B) Representative dot plots for GFP+ cells in GF colonic cells stimulated with 0 (CBL–), 10, 50, or 100 μg/mL CBL. (C) Using flow cytometry, we determined 
frequencies of GFP-expressing CD4+ T cells (CD4+CD3+) or B cells (CD19+B220+) as a percentage of total T or B cells using control WT (GFP–) cells that stained 
with the same antibodies as target samples. (D) Supernatant levels of IL-10 and IL-12p40 were measured by ELISA, and IL-10/IL12 p40 ratios were calculat-
ed. Data are presented as median of 8 separated cell cultures, with cells in each culture pooled from 2–4 mice, combined from 3 independent experiments. 
*P < 0.05, **P < 0.01, ***P < 0.001, Kruskal-Wallis test with Dunn’s post hoc test.
Luminal bacteria increase the regulatory capacity of intestinal 
IL-10–secreting B cells ex vivo. Having established that resident micro-
biota induces in vivo IL-10 expression in the colon and that endog-
enous IL-10 inhibits proinflammatory responses, we next charac-
terized the IL-10–secreting immune cell types that were activated 
following ex vivo cecal bacterial lysate (CBL) treatment of cul-
tured, unfractionated colon LP cells from GF versus SPF Il10+/EGFP 
mice. We have used CBL from SPF WT mice to replicate physiolog-
ic bacterial stimulation in previous ex vivo cellular activation stud-
ies (5, 21, 23). In the current experiments, ex vivo CBL stimulation 
significantly increased the percentage of GFP+ immune cells in a 
dose-dependent manner regardless of the source of cells (GF vs. 
SPF) (Figure 4, A and B). We observed a dose-dependent increase 
in numbers of GFP+ B cells, but not CD4+ T cells, following CBL 
stimulation (Figure 4C). IL-10 protein levels also increased in 
response to CBL stimulation, although the GF LP cells appeared to 
be more sensitive to low concentrations of CBL than did SPF cells, 
so that a dose-dependent response was not seen in GF cells. IL-10 
protein secretion correlated strongly with the frequency of GFP+ B 
cells (r2 = 0.766, P < 0.0001). Levels of IL-12p40, a representative 
inflammatory cytokine that induces Th1/Th17 immune respons-
es, in cells derived from SPF mice steadily decreased as CBL con-
centrations increased, but decreased only with the highest dose of 
CBL in GF cells. These results indicate a bacteria-mediated regu-
latory phenotype with elevated IL-10/IL-12p40 ratios in response 
to a high dose of CBL (Figure 4D).
To examine the role of endogenous IL-10 in regulating in vitro 
induction of proinflammatory IL-12 by intestinal bacterial stim-
ulation, we performed similar studies in cells from IL-10–defi-
cient mice and in WT IL-10–sufficient mouse cells treated with 
neutralizing IL-10R to block IL-10 signaling. High-dose bacterial 
lysate–induced downregulation of IL-12p40 was not seen in LP 
cells from SPF Il10–/– mice (Supplemental Figure 6A), and levels of 
IL-12p40 in these mice were 2- to 3-fold greater than those found 
in WT cells stimulated by the lower doses of CBL (Figure 4D). 
These contrasting results in WT and Il10–/– cells suggest that IL-10 
plays an important role in inducing the regulatory capacity of LP 
cells. This conclusion was confirmed by the observation that anti–
IL-10R antibody administration significantly increased IL-12p40 
production by WT LP cells stimulated ex vivo with high-dose CBL 
(Supplemental Figure 6B).
Bacterial TLR ligands selectively induce IL-10 production by LP 
innate immune cells. Having established that unfractionated bac-
terial microbiota induces IL-10 production by LP CD4+ T cells 
and B cells, we next sought to identify the bacterial components 
that induce IL-10 production by colonic LP cells. We performed 
in vitro stimulation using representative TLR ligands and lysates 
of representative classes of resident bacteria implicated in IBD 
pathogenesis and mucosal protection. We stimulated colonic LP 
cells from GF mice with (i) the TLR ligands Pam3csk4 (Pam3: TLR 
1/2 agonist), LPS (TLR4 agonist), and CpG-DNA (TLR9 ligand); 
(ii) lysates from putative proinflammatory human bacterial spe-
cies Escherichia coli LF82, Enterococcus faecalis, and Ruminococcus 
gnavus (more prevalent in patients with active IBD and inducers
of experimental colitis in gnotobiotic IL-10–deficient mice; refs.
2, 36); and (iii) a mixture of 17 antiinflammatory strains of human 
Clostridium species that protect against experimental colitis (8)
and are decreased in IBD patients (3, 37). We detected increased
frequencies of GFP+ colon LP B cells in cultures that were treated
with Pam3 or CpG-DNA (Figure 5, A and B). Frequencies of GFP+ 
macrophages and DCs also increased following ex vivo stimu-
lation with CPG-DNA, but the number of these cells was lower
than that of IL-10–producing B cells by 10- to 25-fold (Figure 5C). 
These results are consistent with a higher level of secreted IL-10
Figure 5. Bacterial products predominantly 
expand GFP+ B cells and innate immune 
cells ex vivo. Unfractionated colonic LP cells 
from GF Il10+/EGFP reporter mice were cultured 
without (–, media only) or with 200 ng/mL 
LPS, 50 ng/mL Pam3csk (Pam), 1 nM CpG-
DNA (CpG), 10 μg/mL lysates of E. coli LF82 
(Ec), E. faecalis (Ef), or R. gnavus (Rg) or a 
mixture of 17 strains of Clostridia species 
(Clo). (A) Frequencies of GFP-expressing cell 
types were determined by flow cytometry 
using antibodies to cell surface markers as 
described in Methods. Data are presented 
as median of 4 separate cell cultures, with 
cells in each culture pooled from 2–4 mice; 
*P < 0.05, **P < 0.01, ***P < 0.001 (vs. 
no stimulation), Kruskal-Wallis test with 
Dunn’s post hoc test. (B) Representative dot 
plots for GFP (IL-10)+ B cells stimulated with 
or without CpG or Pam3. (C) Summary pie 
charts for cell populations expressing GFP.
following ex vivo stimulation of colonic LP cells with Pam3 and 
CPG (Supplemental Figure 6C). The frequencies of GFP+ CD4+ 
T cells were not significantly altered by any of the in vitro stimu-
li tested (Figure 5A). These data indicate that ex vivo stimulation 
with bacterial products preferentially induces increased numbers 
of immunoregulatory IL-10–producing B cells compared with 
CD4+ T cells. CD4+ T cells may require additional signals, longer 
activation times, or specific antigenic stimulation of interacting 
APCs that are more efficient in vivo to produce IL-10.
In vivo exposure to resident microbiota programs protective B cell 
responses to ex vivo bacterial stimulation of IL-10 and inflammatory 
cytokine production. Given that treatment with CBLs and selected 
TLR ligands increased the frequency of IL-10–producing B cells 
and IL-10 production in ex vivo cultures of LP cells isolated from 
GF mice, we next examined (i) whether in vivo exposure to resident 
microbiota influences innate immune responses to ex vivo bacteri-
al products and (ii) whether these products differentially activate 
protective IL-10 and a key proinflammatory cytokine, IL-12p40. 
We stimulated colonic LP B cells from GF and SPF mice first with 
a physiologic colonic microbiota lysate, CBL, then with represen-
tative bacterial lysates and TLR ligands. We measured the relative 
induction of IL-10 and IL-12p40 secretion by ELISA. CBL-stim-
ulated intestinal (MLN and colon LP) B cells produced abundant 
IL-10 ex vivo regardless of the source of cells (GF vs. SPF) (Figure 
6A). However, IL-12p40 production by CBL-stimulated intestinal B 
cells from SPF mice was significantly lower than from B cells derived 
from GF mice, resulting in a more protective phenotype, as indicat-
ed by increased IL-10/IL-12p40 ratios in CBL-stimulated SPF B cells 
(Figure 6A). Blockade of IL-10 signaling with anti–IL-10R antibody 
increased IL-12p40 production in both SPF and GF colonic B cells, 
Figure 6. Enteric resident bacteria in mice increase the capacity of intestinal B cells to suppress ex vivo bacterial lysate–stimulated inflammatory 
cytokine production that is mediated by IL-10 signaling. (A) Cytokine secretion by 10 μg/mL CBL-stimulated colonic LP B cells isolated from GF or SPF-
raised WT mice in culture for 2 days. Cytokine concentrations were measured by ELISA. Data are presented as median of 6–7 separate cell cultures, with 
cells in each culture pooled from 3–4 mice. Mann-Whitney U test (GF vs. SPF). *P < 0.05, **P < 0.01, ***P < 0.001. (B) Colonic B cells from GF or SPF-reared 
WT mice were cultured with anti–IL-10R or isotype control antibodies in the presence or absence of 10 μg/mL CBL for 24 hours. Supernatant levels of 
IL-12p40 were measured by ELISA. Data are presented as median of 4 separate cell cultures, with cells in each culture pooled from 2–4 mice; *P < 0.05, 
Kruskal-Wallis test with Dunn’s post hoc test. (C) Cytokine secretion by MLN B cells from GF or SPF-raised WT mice cultured for 2 days with the indicated 
bacteria lysates or TLR ligands (see Figure 5 legend). IL-10 and IL-12p40 in culture supernatants were measured by ELISA. Data are presented as median of 
4 separate cell cultures, with cells in each culture pooled from 3–6 mice. *P < 0.05, **P < 0.01, ***P < 0.001 (vs. no stimulation), Kruskal-Wallis test with 
Dunn’s post hoc test; #P < 0.05, ##P < 0.01 (GF vs. SPF), Mann-Whitney U test.
Pam3, CpG-DNA, and E. coli LF82 lysate (Figure 6C). However, 
while secretion of IL-10 by stimulated MLN B cells was similar in 
GF and SPF mice, MLN B cells from SPF-raised animals produced 
less IL-12p40 compared with GF mice when treated with lysates 
of E. faecalis, R. gnavus, and Clostridium species, and with Pam3 
but not CpG-DNA. IL-10/IL-12p40 ratios were also higher in cul-
tures of cells from SPF versus GF mice for R. gnavus, Clostridia, 
and Pam3 stimuli (Figure 6C). These observations are similar to 
those in CBL-stimulated MLN B cells (Figure 6A). In aggregate, 
these results demonstrate that intestinal B cells acquire a strong 
regulatory (tolerogenic) phenotype following in vivo exposure to 
complex resident bacteria that is maintained by continuous ex 
vivo stimulation with TLR2 and -9 ligands.
IL-10–secreting B cells are induced and inhibit colitis in a TLR2- 
and MyD88-dependent manner. Based on our observations that in 
vitro exposure of resident microbiota and bacterial TLR ligands 
indicating that IL-10 signaling is essential for inducing a regulatory 
phenotype in mucosal B cells (Figure 6B). To assess the functional 
significance of physiologic bacterial lysate activation of regulatory 
B cells, we created B cell/T cell (CD4+) cocultures with and with-
out CBL stimulation and measured T cell proliferation and effector 
cytokine production. Colonic B cells from SPF WT mice suppressed 
T cell proliferation and IFN-γ and IL-17a production in a B cell num-
ber–dependent manner with, but not without, CBL stimulation (Sup-
plemental Figure 7, A–C). These results illustrate the importance of 
resident enteric microbiota and IL-10 signaling for the healthy devel-
opment and function of intestinal regulatory B cells.
To identify the specific bacterial species and components that 
stimulate B cells to secrete IL-10, we treated MLN B cells from GF 
versus SPF mice with the spectrum of bacterial species lysates and 
TLR ligands described in the experiments shown in Figure 5. Both 
GF and SPF MLN B cells secreted abundant IL-10 in response to 
Figure 7. TLR2/MyD88 signaling increases the frequency of IL-10–producing B cells upon bacterial product stimulation ex vivo and mediates the suppression 
of experimental colitis by IL-10–producing B cells in vivo. (A) Colonic LP B cells from 8- to 10-week-old WT Il10+/EGFP, Tlr2−/− Il10+/EGFP, Tlr4−/− Il10+/EGFP, and Myd88−/− 
Il10+/EGFP mice were cultured without (–) or with 10 μg/mL CBL, 50 ng/mL Pam3, or 200 ng/mL LPS for 24 hours, after which IL-10 levels in culture supernatants 
were measured by ELISA (top panel). GFP+ populations in B cells (live CD45+CD19+B220+) were analyzed with flow cytometry in reference to WT (GFP–) control 
cells stained with the same antibodies as target samples. Data are presented as median of 7–8 separate cell cultures, with cells in each culture pooled from 2–3 
mice, combined from 3 independent experiments (bottom panel). *P < 0.05, **P < 0.01. (B) Eight-week-old GF Il10+/EGFP reporter mice were conventionalized with 
SPF fecal bacterial transplantation. Mice were given anti-TLR2 antibody (αTLR2) or isotype control i.v. on days 0 and 4 after fecal bacterial transplantation and 
harvested on day 7 for IL-10 analysis. Colonic LP cells were isolated, and live CD45+GFP+ B cells (CD19+B220+) were analyzed by flow cytometry (left) as described 
above; Il10 mRNA levels were normalized with Actb (right). n = 4–5 mice. Data are presented as median, Mann-Whitney U test. (C and D) Splenic B cells (1 × 106) 
from SPF-raised WT, Tlr2−/−, Tlr4−/−, Myd88−/−, or Il10−/− mice were cotransferred with 5 × 105 WT naive CD4+ T cells isolated by a naive CD4+ T cell isolation kit (see 
Methods, Cell purification) into SPF Rag2−/− Il10−/− recipients. Six weeks after cell transfer, mice were evaluated for (C) severity of colitis by histology and (D) mea-
surement of spontaneously secreted IL-10 and IFN-γ in colonic tissue explants by ELISA. n = 7–9 mice/group, combined from 2 independent experiments. Data 
are presented as median; *P < 0.05 and **P < 0.01 (vs. WT mice), Kruskal-Wallis test with Dunn’s post hoc test.
tion of IL-10 by cultured LP B cells without ex vivo stimulation 
(Figure 7A and Supplemental Figure 8A). However, ex vivo CBL 
stimulation of cultured colonic LP cells significantly increased 
IL-10 secretion and the proportion of GFP+ B cells in a TLR2/
MyD88-dependent, but TLR4-independent, manner (Figure 7A 
and Supplemental Figure 8A). As expected, LPS and Pam3 stim-
ulation of cultured colonic LP cells increased IL-10 secretion and 
the proportion of GFP+ B cells in a TLR4/MyD88-dependent and 
TLR2/MyD88-dependent manner, respectively (Figure 7A). As in 
other experiments, the number of GFP+ B cells strongly correlated 
with IL-10 protein production (r2 = 0.724, P < 0.0001). We then 
verified that B cells are a primary source of IL-10 production fol-
lowing ex vivo intestinal bacterial stimulation in the absence of 
other cell populations (Supplemental Figure 9). These data sug-
gest that in Tlr2–/– or Myd88–/– mice, TLR2/MyD88-dependent 
IL-10 production by B cells is not due to abnormal immune activa-
induces IL-10–secreting mucosal cells, including B cells with a 
regulatory phenotype, we next sought to determine (i) whether 
TLR signaling helps develop physiological or bacteria-induced 
IL-10–secreting mucosal cells; and (ii) whether this pathway 
mediates mucosal protection by regulatory B cells. Based on our 
observations that a TLR2 ligand consistently activated IL-10 pro-
duction, we created SPF Il10+/EGFP Tlr2–/–, Il10+/EGFP Tlr4–/–, and 
Il10+/EGFP Myd88–/– double mutants to enable in vivo and ex vivo 
functional studies. We used TLR4 as a thoroughly investigated 
parallel pathway for LPS- and Gram-negative bacteria–induced 
activation and MyD88 as a common TLR2 and TLR4 downstream 
signaling molecule. We first quantified IL-10–secreting cells in the 
colon LP of these mice in vivo and after ex vivo stimulation with 
the TLR ligands LPS, Pam3, and CBL. We found that the absence 
of TLR2, TLR4, or MyD88 signaling did not significantly alter 
either the percentage of colonic LP GFP+ B cells or basal secre-
Figure 8. The PI3K/AKT pathway is involved in TLR2-dependent IL-10 production by CBL-stimulated B cells and their regulatory effect on T cell–mediated 
colitis. Splenic B cells (1 × 106/well) from 8- to 10-week-old SPF WT, Tlr2−/−, and Tlr4−/− mice were cultured without or with 10 μg/mL CBL. Cells were harvested 
0, 15, 30, and 60 minutes after CBL stimulation, and phosphorylation of AKT was analyzed by Western blot. (A) Representative blots and (B) densitometric 
analysis of phospho-AKT/AKT are shown. n = 5 mice/group, combined from 2 independent experiments. *P < 0.05, **P < 0.01, Kruskal-Wallis test with 
Dunn’s post hoc test. (C) Splenic B cells (1 × 106/well) from 8- to 10-week-old SPF Il10+/EGFP mice were cultured with 1 μM pan-PI3K inhibitor wortmannin 
(Wort) or Ly294002 (Ly), 1 μM PI3Kp110δ-specific inhibitor IC-87114 (IC), or DMSO alone, with stimulation with 10 μg/mL CBL for 48 hours. Supernatant levels 
of IL-10 and IL-12p40 were measured by ELISA. (D) GFP+ population in B cells (live CD45+CD19+B220+) were analyzed by flow cytometry in reference to WT 
(GFP–) control cells stained with the same antibodies as target samples. Data are presented as median of 6 separate cell cultures, combined from 2 indepen-
dent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, Kruskal-Wallis test with Dunn’s post hoc test. (E) Splenic B cells (5 × 105/well) from 8- to 10-week-old 
SPF WT and PI3Kp110δKI mice were cultured with 10 μg/mL CBL for 48 hours. Supernatant levels of IL-10 were measured by ELISA. Data are presented as 
median. n = 4 mice, combined from 2 independent experiments. *P < 0.05, Mann-Whitney U test. (F) Splenic B cells (1 × 106) from SPF-raised WT or PI3K-
p110δKI mice were cotransferred with WT naive CD4+ T cells (5 × 105) isolated by a naive CD4+ T cell isolation kit into SPF Rag2−/− Il10−/− recipients. Six weeks 
after cell transfer, mice were evaluated for severity of colitis by histology and measurement of spontaneously secreted IL-10 levels in colonic tissue explants 
by ELISA. n =7–9 mice/ group, combined from 2 independent experiments. Data are presented as median; *P < 0.05, Mann-Whitney U test.
performed targeted inhibitor studies using CBL-stimulated B 
cell production of IL-10 and IL-12p40 (Figure 8C). We found 
that PI3K, including the PI3Kp110δ subunit, was involved in 
CBL-stimulated IL-10 production by B cells and regulatory func-
tion characterized by an increased IL-10/IL-12p40 ratio (Figure 
8C). Increased CBL-stimulated GFP+ B cell frequency was also 
inhibited by pan-PI3K and PI3Kp110δ-specific inhibitors (Figure 
8D and Supplemental Figure 12). PI3K110δKI B cells were neither 
able to produce abundant IL-10 following in vitro CBL stimu-
lation (Figure 8E) nor ameliorate T cell–mediated colitis in the 
CD4+ T and B cell cotransfer model (Figure 8F). Together, our in 
vivo and in vitro studies indicate that protective IL-10 production 
by B cells is activated by CBL through TLR2 and downstream sig-
naling through the PI3K (p110δ subunit) pathway.
Discussion
In this study, we describe the kinetics of in vivo development of 
IL-10–secreting intestinal B cells and subsets of CD4+ T cells in 
ex-GF Il10+/EGFP reporter mice colonized with enteric resident 
microbiota and the importance of TLR2 and PI3K signaling in the 
induction of protective resident bacteria–induced IL-10–produc-
ing B cells.
The consortium of resident enteric bacteria provides protec-
tive signals to host immune defenses (40–42). Colonization of 
GF WT mice with resident fecal microbiota rapidly stimulated 
mucosal proinflammatory cytokine production manifested by 
transient release of TNF-α, IL-12p40, and IFN-γ, but not IL-17a, 
within 3 days, while intestinal IL-10 levels gradually increased 
to maximum sustained levels in 7 days (43). The finding that 
transient in vivo stimulation of proinflammatory cytokine gene 
expression was followed by downregulation to basal levels in 
ex-GF Il10+/+ but not in Il10–/– mice advances the hypothesis that 
resident microbiota induces IL-10 production by LP immune 
cells that mediates mucosal homeostasis. That neutralization of 
IL-10 signaling in B cells by anti–IL-10R antibody potentiated 
physiologic bacterial stimulation of IL-12p40 further supports 
our hypothesis. These results are consistent with our previous 
work showing that in vivo administration of anti–IL-10R anti-
body prevented downregulation of ex vivo bacterial antigen–
stimulated Th1 immune responses in ex-GF mice colonized with 
enteric bacteria (13).
Based on our current and previous observations, we propose 
that induction of IL-10 by enteric resident bacteria is essential for 
maintaining intestinal mucosal homeostasis. Our studies included 
several features that we believe to be novel: the use of GF Il10+/EGFP 
reporter (Vert-X) mice to study the in vivo kinetics of IL-10 acti-
vation after colonization with resident enteric bacteria; identifi-
cation of the colonic LP cell types that produce IL-10 following 
microbial colonization; and the study of the signaling pathways of 
IL-10 induction by physiologic resident bacterial stimulation. Our 
use of GFP+ cells as indicators of cellular IL-10 production was val-
idated by the strong correlations we found between the frequency 
of GFP+ cells and both IL-10 RNA transcription and IL-10 protein 
secretion following bacterial stimulation. Previous studies of sys-
temic IL-10–secreting immune cells have relied on nonphysiolog-
ic, ex vivo stimulation of cultured immune cells (i.e., anti-CD40, 
anti-CD3/CD28, or concanavalin A [ConA]) or on mice with sep-
tion by other cell types, for example, aberrant T cell activation. On 
the other hand, CBL-stimulated IL-12p40 production by unfrac-
tionated colonic LP cells was not altered by lack of TLR signaling 
(Supplemental Figure 8B), likely due to predominant IL-12p40 
production by non-B cell populations (i.e., macrophages and DCs) 
by other stimulatory pathways. In aggregate, these results demon-
strate that global resident bacterial induction of IL-10–secreting B 
cells ex vivo is TLR2 and MyD88 dependent. In addition, in vivo 
blockade of TLR2 by anti-TLR2 antibody in GF Il10+/EGFP reporter 
mice during colonization with SPF bacteria resulted in diminished 
numbers of colonic GFP+ B cells and decreased colonic Il10 mRNA 
expression (Figure 7B). These results emphasize the importance of 
TLR2 signaling in enteric bacteria–mediated, intestinal IL-10–pro-
ducing B cell development and activation.
Based on these results showing TLR2/MyD88-dependent 
induction of IL-10–producing B cells in vivo and in vitro, we exam-
ined the regulatory function of bacteria-induced IL-10–secreting 
B cells in vivo using our established CD4+ T and B cell cotransfer 
colitis model (23). We cotransferred splenic naive CD4+ T cells 
from WT mice with or without splenic B cells isolated from SPF-
raised WT, Tlr2–/–, Tlr4–/–, Il10–/–, and Myd88–/– mice into Il10–/– 
Rag2–/– mice, and evaluated the severity of colitis 6 weeks after 
cell transfer. Transferred WT and Tlr4–/– B cells substantially 
suppressed histological evidence of colonic inflammation (Figure 
7C and Supplemental Figure 10) and were associated with lower 
spontaneous IFN-γ secretion, higher spontaneous IL-10 secretion, 
and elevated IL-10/IFN-γ ratios by colonic explants (Figure 7D). 
On the other hand, B cells lacking IL-10, TLR2, or MyD88 exhib-
ited no protective function (Figure 7, C and D, and Supplemental 
Figure 10), although transferred Tlr2–/– B cells were present in the 
colon (data not shown). Based on these results in the T and B cell 
cotransfer colitis model, we propose that mucosal IL-10–secreting 
B cells protect against chronic colitis in a microbiota-dependent 
manner through selective TLR signaling.
TLR2-specific CBL activation in B cells activates the PI3K/AKT/
glycogen synthase kinase 3β signaling pathway. Since colonization 
with resident microbiota or ex vivo stimulation with CBL induces 
IL-10 production by colonic B cells with a regulatory phenotype 
in a TLR2-dependent fashion, we next explored downstream 
signaling pathways by measuring activation of signaling com-
ponents by Western blotting and selective pharmacologic and 
genetic blockade of key signaling molecules. We first investigat-
ed the TLR2-specific activation of the PI3K/AKT pathway, which 
has been found to facilitate IL-10 production (31, 38, 39). We cul-
tured colonic LP B cells from SPF WT, Tlr2–/–, and Tlr4–/– mice 
with CBL, and measured phosphorylation of AKT, a key down-
stream molecule in thePI3K pathway. We found that phosphor-
ylation of AKT was activated to a significantly lesser extent by 
CBL in Tlr2–/– B cells compared with WT and Tlr4–/– B cells (Fig-
ure 8, A and B). We also observed that the PI3K pathway–related 
molecules PDK and glycogen synthase kinase 3β (GSK3β), but 
not p85, were activated in a TLR2-dependent manner, while the 
Myd88 signaling–associated molecules p38 and ERK were not 
dependent on TLR2 activation (Supplemental Figure 11, A and 
B). These results indicate that CBL stimulation preferentially 
activates the PI3K/AKT/GSK3β signaling pathway downstream 
of TLR2 in B cells. To confirm these findings functionally, we 
cient B cells attenuated colitis in a T and B cell cotransfer CD4+ 
colitis model, specifically through the p110δ subunit. Similarly, 
TLR2-dependent PI3K signaling has been reported to mediate 
phagocytosis of pathogens by macrophages, and PI3Kp110δ regu-
lates APC activation of Th1/Th17 cells and colitis (39, 50).
We demonstrated that in vivo microbial activation of colon-
ic B cells and continued exposure to bacterial components was 
important for their homeostatic function. We observed that with 
ex vivo bacterial activation, GF mucosal B cells, compared with 
SPF mucosal B cells, produced equal amounts of IL-10, but higher 
levels of the inflammatory cytokine IL-12p40. These results show 
that in vivo exposure to resident microbiota enhances the regu-
latory capacity of intestinal B cells by selectively downregulating 
production of bacteria-stimulated inflammatory cytokines, but 
not IL-10. We previously demonstrated that with in vivo bacterial 
exposure, transferred GF WT B cells acquire regulatory pheno-
types that help ameliorate colitis, with effects similar to those of 
B cells derived from SPF WT mice (23). In the current study, we 
showed that SPF B cells were unable to suppress effector T cell 
function in vitro without continued CBL exposure. These obser-
vations indicate that continuous bacterial stimulation is required 
in order to maintain regulatory B cells. Others have shown that 
bacterial colonization reduces the IL-10–mediated inflammatory 
hyporesponsiveness present in GF animals and makes them less 
susceptible to infection (40). We further demonstrated that in vivo 
physiologic intestinal microbial colonization selectively activated 
IL-10 production by subsets of intestinal LP T and B cells, with 
no concomitant stimulation of IL-10–producing cells in MLN and 
splenic cells in the same mice. These findings are consistent with 
the lack of differences in the number or function of IL-10–pro-
ducing peritoneal regulatory B cells in GF versus SPF mice (28). 
The results emphasize the important site-specific interactions 
between the microbiota and intestinal regulatory B cells in medi-
ating mucosal homeostasis.
We also explored the ability of the microbiota to induce T cell 
production of IL-10. Bacterial colonization of GF mice markedly 
increases intestinal GFP+ Tr1 cells (Foxp3negCD25–CD4+ T cells) 
and RORγt+Foxp3+GFP+CD4+ T cells (33, 34, 51), which made up 
only a small portion of the total number of GFP+CD4+ T cells. In 
contrast, ex vivo intestinal bacterial stimulation of immune cells 
predominantly increased GFP+ IL-10–producing B cells but not 
CD4+ T cells. The lack of TLR/MyD88 signaling did not affect the 
frequency or activity of mucosal Tr1 cells either in vivo or ex vivo. 
These results suggest that resident enteric bacteria–stimulated Tr1 
cell induction is TLR/MyD88 independent. Why different path-
ways are required for activation of IL-10–producing B and Tr1 cells 
is not entirely clear. CD4+ IL-10–producing T cells may require 
physiologic stimulation by live bacterial antigens or metabolites, 
such as butyrate (52), rather than bacterial lysates; longer incu-
bation periods with other signals not present ex vivo, or interac-
tions with epithelial or mesenchymal cells. Cong and colleagues 
demonstrated that IL-10–secreting Tr1 cells from SPF mice were 
expanded by CBL antigen-pulsed APCs in vitro and that a CBL- 
responsive Tr1 clone could inhibit colitis in a T cell cotransfer 
model (53). We recently showed that Tr1 cells were induced by 
IL-10–producing B cells ex vivo in the presence of CBL when 
equal numbers of APCs and naive T cells were cocultured, a ratio 
tic, infectious, or autoimmune disease (32). Cells isolated from 
normal mice typically require prestimulation with nonspecific 
agents such as PMA/ionomycin to detect and analyze cell-specific 
IL-10 secretion by flow cytometry (44). Our physiologic approach 
using GF Il10+EGFP reporter mice allowed us, without additional 
nonphysiologic stimulation, to more accurately detect and quan-
tify the effects of complex intestinal microbiota lysates, specific 
bacterial species, and defined bacterial products on IL-10–produc-
ing cells in vitro; and the effects of in vivo physiologic colonization 
by complex resident microbiota on IL-10–producing cells in differ-
ent mouse tissues over time.
Our somewhat unexpected observation that bacterial coloni-
zation of GF mice increased the frequency of colonic IL-10–pro-
ducing B cells, in addition to subsets of CD4+ T cells, led us to 
investigate the roles of IL-10–producing B cells in maintaining 
mucosal homeostasis and the signaling pathways involved in 
IL-10 induction by resident microbiota (23–28). Our results and 
observations by others suggest that bacterial stimulation through 
the MyD88 pathway activates Il10 expression and causes B cells 
to produce IL-10, which helps maintain gut homeostasis. B cell–
specific Myd88–/– mice are more susceptible to dextran sulfate 
sodium–induced mucosal damage compared with mice lacking 
MyD88 in other cell types, including T cells, macrophages, DCs, 
and epithelium (45). In the present study, we demonstrated that 
ex vivo activation of the TLR2/MyD88 pathway is essential for 
induction of bacteria-activated mucosal IL-10–producing B cells, 
but not T cells. However, the absence of TLR signaling through 
MyD88 did not alter the relative number of mucosal IL-10–pro-
ducing B cells in SPF-raised animals in vivo, indicating that phys-
iologic development of intestinal IL-10–producing B cells is TLR 
independent, although in vivo protection against colitis by B cells 
is IL-10, TLR2, and MyD88 dependent. We postulate that bas-
al activation of in vivo IL-10–producing B cells and ex vivo bac-
teria-stimulated IL-10–secreting B cells likely requires different 
pathways in response to actively metabolizing resident intestinal 
bacteria, or that this activation depends on complex interactions 
with cell types not represented in our in vitro cultures. Similar 
disparities exist in the regulation of IL-10–producing CD4+ cells, 
which increased in frequency following colonization of GF mice 
with SPF microbiota but are not activated ex vivo by physiologic 
cecal microbial lysates. Resolving these disparities will require 
further mechanistic studies.
We showed that upstream of MyD88 signaling, TLR2, but not 
TLR4, signaling increased the numbers of bacterially activated 
GFP+ B cells and B cell IL-10 secretion, which contributed to B cell 
attenuation of T cell–mediated colitis. These TLR2 signaling find-
ings represent what we believe to be a novel molecular mechanism 
of bacteria-stimulated, intestinal IL-10–producing B cells. Other 
investigators have shown that certain subsets of resident enteric 
bacteria induce regulatory immune responses, including IL-10 
secretion, via TLR2 signaling (9, 46–49). Likewise, cecal lumi-
nal lysates and SPF bacteria appeared to preferentially activate 
mucosal IL-10–producing regulatory immune cells through TLR2. 
An important mechanistic observation from our study is that 
TLR2-mediated CBL stimulation of B cell production of IL-10 is 
mediated through activation of PI3K/AKT/GSK3β signaling. Fur-
thermore, we demonstrated that WT but not PI3K signaling–defi-
Cell purification. MLN or colon LP B cells were purified magnet-
ically by positive selection with anti-CD19 microbeads after nega-
tive selection using a mixture of anti-CD90.2, anti-CD11c, and anti-
Ter119 microbeads. Final CD19+ cell fractions were confirmed to be 
greater than 99.5% pure by flow cytometry, while cell viability was 
shown to be greater than 88% by eosin Y exclusion. In some experi-
ments, colon LP cells were separated into B cell and non-B cell popu-
lations with anti-CD19 MicroBeads. Naive CD4+ T cells were isolated 
by use of a Naive CD4+ T Cell Isolation Kit, Mouse, and confirmed to 
be greater than 94.7% pure and 95% viable. All microbeads including 
the naive CD4+ T cell isolation kit used in this study were purchased 
from Miltenyi Biotec.
Bacterial lysate. CBL was prepared from the contents of ceca from 
SPF-raised C57BL/6 WT mice as described previously (21). Lysates of 
each bacteria strain were prepared from individual colonies of E. coli 
LF82, E. faecalis, and R. gnavus, as previously described (36). A lysate of 
Clostridia was prepared from the cecal contents of ex-GF mice selec-
tively colonized with a mixture of 17 strains of Clostridium species (8).
Cell cultures. Unfractionated MLN cells (1 × 106) or colon LP cells 
isolated from GF or SPF-raised Il10+/EGFP mice were cultured in 200 μl 
medium/well (96-well plates) for 24–72 hours at 37°C with 5% CO2. 
The culture medium was RPMI 1640 (Gibco, Invitrogen) containing 
10% FBS, 1% penicillin-streptomycin-amphotericin B (Gibco, Invitro-
gen), and 5 × 10–5 mol/L 2-mercaptoethanol (Sigma-Aldrich) with or 
without the following bacterial products; 10, 50, or 100 μg/mL CBL; 
10 μg/mL lysate of Clostridia, E. coli LF82, E. faecalis, or R. gnavus; 200 
ng/mL LPS, and 50 ng/mL Pam3CSK4 (InvivoGen) or 1 nM CpG-DNA 
(Sigma-Aldrich). In some experiments, 1 μM of the pan-PI3K inhibitor 
wortmannin (Sigma-Aldrich) or Ly294002 (Sigma-Aldrich); 1 μM of 
the PI3Kp110δ-specific inhibitor IC-87114 (Sigma-Aldrich); or vehicle 
(DMSO) alone was added at various concentrations indicated in the 
Figure legends. Following cell culture, the supernatants were collected 
for measurements of cytokines by ELISA, while cells were analyzed by 
flow cytometry.
Cytokine measurements. IFN-γ, IL-12/23p40, or IL-10 ELISAs were 
performed by the Immunoassay Core of the UNC Center for Gastro-
intestinal Biology and Disease using the following products: mouse 
anti–IL-10, –IL-12/23p40, and –IFN-γ (BD Biosciences) as previously 
described (21, 23). Concentrations of cytokines were established in 
triplicate culture supernatants by comparison with standard curves 
generated using the appropriate recombinant cytokine per the manu-
facturer’s instructions.
Real-time PCR. Total RNA was isolated from distal colon using 
the RNeasy Micro Kit (QIAGEN). First-strand complementary DNA 
was synthesized from 1 μg total RNA using M-MLV Reverse Transcrip-
tase (Gibco, Invitrogen) according to the manufacturer’s instructions. 
Quantitative reverse transcription PCR was performed on a Master-
cycler ep realplex 2S (Eppendorf) using the SYBR Green quantitative 
PCR SuperMix (Invitrogen) to quantify gene expression. The PCR 
primers used in this study were reported previously (21, 23, 54). Each 
complementary DNA sample was analyzed in duplicate or triplicate 
for quantitative assessment of RNA amplification, and the results are 
expressed relative to the housekeeping gene β-actin.
Immunohistochemistry. Distal colons were harvested, fixed with 
4% paraformaldehyde (Sigma-Aldrich), and embedded in O.C.T. 
compound (Sakura). Tissue sections (5 μm) were blocked with TNB 
buffer (PerkinElmer) for 30 minutes at room temperature and incu-
 
considerably higher than the ratio of APCs to T cells in the intes-
tinal LP (23). In these ex vivo coculture studies, B cells were the 
primary source of secreted IL-10. Our results suggest that ex vivo 
activation of IL-10 by T cells requires boosted antigen presenta-
tion by greater than physiologic numbers of APCs.
In summary, complex resident enteric microbiota selectively 
induced colonic LP IL-10–producing B cells and subsets of CD4+ 
T cells, and increased the regulatory capacity of intestinal B cells. 
Fecal microbiota colonization of GF mice transiently activated 
inflammatory cytokines in the colon, which were subsequently 
downregulated by sustained IL-10 production. These inflamma-
tory cytokines progressively increased from a higher baseline in 
IL-10–deficient mice, which develop colitis dependent on bacte-
rial colonization. Resident bacteria stimulated IL-10 production 
through TLR2, MyD88, and PI3Kp110δ signaling, which mediat-
ed B cell antiinflammatory responses that, in turn, attenuated T 
cell–mediated colitis. We conclude that resident enteric bacteria 
activate IL-10–producing intestinal B cells in a MyD88/TLR2/
PI3K-dependent manner that suppresses aggressive immune 
responses and maintains mucosal homeostasis.
Methods
Further information can be found in Supplemental Methods.
Mice. C57BL/6 WT, Il10−/−, Rag2–/–, Tlr2−/−, Tlr4–/–, and Myd88–/– 
mice were purchased from the Jackson Laboratory. Il10+/EGFP reporter 
(Vert-X) mice have been described previously (32). Pi3kp110δD910A/D910A 
(PI3Kp110δKI) mice were previously obtained from B. Vanhaesebroeck 
(Queen Mary University of London, London, United Kingdom) (39). 
Il10−/−Rag2−/− double-knockout (DKO) mice were generated by crossing 
Il10−/− with Rag2–/– mice. Tlr2−/− Il10+/EGFP, Tlr4−/− Il10+/EGFP, and Myd88−/− 
Il10+/EGFP mice were generated by crossing Tlr2−/− with Il10+/EGFP mice, 
Tlr4−/− with Il10+/EGFP mice, and Myd88−/− with Il10+/EGFP mice, respec-
tively. These mice were maintained in SPF conditions at UNC and were 
used at 8–12 weeks of age. Il10+/EGFP, WT, and Il10–/– mice were derived 
into GF conditions by embryo transfer and maintained in the UNC Cen-
ter for Gastrointestinal Biology and Disease Gnotobiotic Core. In some 
experiments, GF mice were inoculated with feces from SPF WT mice.
Cell isolation. Mononuclear cells were isolated from colonic LP, 
MLN, and spleen as described previously (24). MLNs were crushed 
through 70-μm filters into PBS with 2.5% FBS (Gibco, Invitrogen). 
Spleens were mechanically dissociated, and red blood cells were 
lysed with Red Blood Cell Lysing Buffer (Sigma-Aldrich). For isola-
tion of colonic LP lymphocytes (LPLs), colons were washed with cold 
PBS, opened longitudinally, and cut into 10-mm pieces. Intestinal 
fragments were incubated in 1 mM DTT (Sigma-Aldrich) in Ca2+- and 
Mg2+-free HBSS (Gibco, Invitrogen) for 15 minutes at room tempera-
ture. Next, the tissues were incubated in 1 mM EDTA (Sigma-Aldrich) 
in HBSS for 20 minutes at 37°C with shaking, which was repeated 
after a thorough washing. The cell suspensions were removed, and 
remaining fragments were transferred to flasks containing HBSS 
with 1 mg/mL collagenase type III (Sigma-Aldrich) and 1% penicil-
lin-streptomycin (Gibco, Invitrogen), then stirred gently for 60 min-
utes at 37°C. Cell suspensions containing LPLs were filtered through 
a nylon mesh and centrifuged; then the LPLs were purified using a 
44%/70% discontinuous Percoll gradient (GE Healthcare). After 
centrifugation at 800 g for 20 minutes at 22°C, mononuclear cells 
were collected from the interface.
Flow cytometry. Spleen, MLN, and colonic LP cells were incu-
bated for 15 minutes at 4°C with anti-CD16/CD32 (BD Bioscienc-
es) to block Fc receptors and then for 20 minutes at 4°C with 6–7 
fluorochrome-conjugated antibodies (Supplemental Table 1) to 
evaluate the cell phenotype. All sample cells were stained with 
LIVE/DEAD Fixable Dead Cell Stain Kit (Near-IR, Thermo Fish-
er Scientific) and Pacific Orange–conjugated CD45 along with the 
following: PE, PE-Cy5, PE-Cy7, Pacific blue, allophycocyanin, or 
equivalent fluorescence-conjugated antibodies; B220 and CD19 
for B cells; CD3 and CD4 for CD4+ T cells; CD3 and CD8 for CD8+ 
T cells; CD11b and CD11c for DCs; CD11b and F4/80 for macro-
phages; or CD3 and CD49b for NK cells. In addition, target anti-
bodies or isotype control antibodies were simultaneously added. 
Enumeration of cells expressing Foxp3 or RORγt was performed by 
intracellular staining with the Fixation/Permeabilization Solution 
Kit according to the manufacturer’s instructions (BD Biosciences) 
or fixation buffer (PBS containing 4% paraformaldehyde; Electron 
Microscopy Sciences), 0.01% Tween-20 (Thermo Fisher Scientif-
ic), permeabilization buffer (PBS containing 0.1% Triton X-100; 
MP Biomedicals), 0.5% BSA (Sigma-Aldrich), and 2 mM EDTA. 
Cells were washed and then analyzed on a CyAn ADP flow cytome-
ter (Beckman Coulter) or LSR II (BD Biosciences) at the UNC Flow 
Cytometry Core Facility. Cells from SPF-raised WT C57BL/6 (GFP–) 
mice were used to determine GFP basal intensity and set the GFP 
gate when Il10+/EGFP reporter cells were used. These WT cells were 
stained with the same antibodies as target cells except for GFP, as 
a fluorescence minus one (FMO) control to assure that spillover or 
spread from other fluorophores would not contribute to the signal 
in the GFP detector. Suitable positive control staining samples or 
IL-10 reporter cells were used for compensation. Seven parame-
ters, including GFP channel, were used for running flow cytome-
try. Gated live CD45+ cells were analyzed with Summit 5.2 software 
(Beckman Coulter) or FlowJo version 10.3.
Transfer of CD4+ T and B cells. DKO mice received i.p. injections of 
5 × 105 splenic CD4+ cells with or without 1 × 106 splenic B cells from 
WT, Il10–/–, Myd88–/–, or PI3Kp110δKI donors. Cells were harvested 6 
weeks after cell transfer, according to Association for Assessment of 
Laboratory Animal Care–approved (AALAC-approved) methods.
Evaluation of colitis. Colitis severity was evaluated by histopa-
thology scoring and cytokine ELISAs on culture media from colon-
ic tissue explants. For histology, intestinal tissues were removed 
at necropsy and fixed in 10% buffered formalin. Paraffin sections 
were prepared and stained with H&E for assessment of colonic 
inflammation by the Histology Core of the UNC Center for Gastro-
intestinal Biology and Disease. Scoring of mucosal inflammation in 
cecum, proximal colon, and distal colon was performed in a blinded 
fashion, with each region being graded from 0 to 4 as described pre-
viously (56). Total histology scores (maximum score of 12) represent 
the summation of the scores from the 3 regions. For colonic tissue 
explant assays, cultures of colon fragments from the recipient mice 
were prepared as described previously (21).
Blockade of TLR2 signaling in vivo. Anti-TLR2 antibody (BioLeg-
end; 100 μg/mouse) or isotype control antibody (purified mouse IgG1, 
κ; BioLegend) was injected i.p. on days 0 and 4 after fecal transplan-
tation with SPF feces. Mice were harvested on day 7, and we evaluated 
colonic GFP+ B cells by flow cytometry, as well as mRNA expression of 
Il10 in distal colon.
bated overnight at 4°C with rabbit anti-GFP antibody (Invitrogen) and 
rat anti–mouse B220 or Armenian hamster anti–mouse CD3 antibody 
(BD Biosciences). Rabbit IgG (Invitrogen) was used as a negative 
control for rabbit anti-GFP antibody. Primary antibodies are listed in 
Supplemental Table 1. After washing, tissue sections were treated with 
DyLight 488–conjugated donkey anti-rabbit IgG and HRP-conjugat-
ed donkey anti-rat IgG or HRP-conjugated donkey anti-hamster IgG 
(Jackson ImmunoResearch Laboratories Inc.). The sections were final-
ly incubated with TSA Plus Cyanine 5 amplification reagent (Perkin-
Elmer) for 10 minutes at room temperature and counterstained with 
DAPI (Sigma-Aldrich). All sections were analyzed by confocal micros-
copy (TCS SP2, Leica).
Western blots. Western blots were performed as previously report-
ed (55). One centimeter of distal colons was homogenized in 1% RIPA 
lysis buffer (Boston Bio Products) containing cOmplete Protease 
Inhibitor Tablet (Roche) and PhosSTOP Phosphatase Inhibitor Tablet 
(Roche) using a Pro200 tissue homogenizer (PRO Scientific). Lysates 
were incubated on ice for an additional 10 minutes at 4°C with rota-
tion. The lysates were cleared of cellular debris by centrifugation, and 
total protein concentration was determined by BCA assay (Thermo 
Fisher Scientific). A total of 30 μg protein from each sample was sepa-
rated by SDS-PAGE using 4%–12% NuPAGE Bis-Tris gels (Invitrogen). 
The separated proteins were transferred onto 0.2-μm nitrocellulose 
membranes and were blocked for 1 hour at room temperature with 
TBS-T (10 mM Tris, 7.5 pH, 150 mM NaCl, and 0.1% Tween-20) con-
taining 10% nonfat dry milk. The membranes were incubated over-
night with anti–phospho-STAT3 (Tyr705; Cell Signaling Technology) 
and then washed 5 times with TBS-T and incubated for 2 hours at 
room temperature with HRP-conjugated goat anti-rabbit IgG second-
ary antibodies (Sigma-Aldrich) (1:40,000 dilution). The membranes 
were developed using SuperSignal West Chemiluminescent Substrate 
(Thermo Fisher Scientific) and were visualized by exposure to blue 
sensitive X-ray film (Genesee Scientific). To confirm even loading, the 
antibodies were removed from the membranes using Restore PLUS 
Western Blot Stripping buffer (Thermo Fisher Scientific), and mem-
branes were blocked as previously described (55) and incubated with 
anti-STAT3 (Cell Signaling Technology) or anti-actin–HRP (Santa 
Cruz Biotechnology) (1:10,000 dilution), followed by HRP-conjugat-
ed goat anti-rabbit IgG secondary antibodies when appropriate.
Following in vitro stimulation of primary B cells with CBL, cells 
were washed with PBS at 4°C, pelleted by centrifugation at 400 g for 
5 minutes at 4°C, and lysed in 1% RIPA buffer containing Complete 
Protease Inhibitor Tablet and PhosSTOP Phosphatase Inhibitor Tablet 
for 10 minutes on ice. Protein lysates were cleared of cellular debris by 
centrifugation, and the lysates were subjected to SDS-PAGE and West-
ern blot as described above in Western blots using anti–phospho–Akt 
(Ser473) antibodies (Cell Signaling Technology; 1:1,000 dilution), fol-
lowed by HRP-conjugated goat-anti-rabbit IgG secondary antibodies 
(Sigma-Aldrich) (1:40,000 dilution). Antibodies were removed from 
the membranes as described above, and even protein loading was con-
firmed using anti-Akt antibodies (Cell Signaling Technology; 1:1,000 
dilution), followed by HRP-conjugated goat anti-rabbit IgG secondary 
antibodies (Sigma-Aldrich; 1:40,000 dilution).
Primary antibodies are listed in Supplemental Table 1. All anti-
bodies were diluted in TBS-T containing 5% nonfat dry milk. Densi-
tometric analysis was performed for all Western blots using ImageJ 
software (version 1.49; NIH).
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